Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Hunan Cancer Hospital
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.
This description comes directly from the study's public registry record.
Huai Liu, MD · +8619918909231 · liuhuai@hnca.org.cn
Always discuss trial participation with your own doctor first.
| Hunan Cancer Hospital | Changsha, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05940532